Efficacy of anti-Apolipoprotein A2 antibody on Kawasaki disease model mice
-
- Ito Fuyu
- Asia International Institute of Infectious Disease Control, General Medical Education and Research Center, Teikyo University,
-
- Suzuki Kazuo
- Research Institute of Disaster Medicine, Chiba University
Bibliographic Information
- Other Title
-
- 川崎病モデルマウスに対する抗ApolipoproteinA2 抗体の有効性
Description
High-dose intravenous immunoglobulin therapy (IVIg therapy) is effective for Kawasaki disease, a vasculitis syndrome. However due to issues that are associated with immunoglobulin preparation, such as the risk of possible contamination by infectious agents and limited blood banking resources, recombinant immunoglobulins are required. Therefore, we cloned recombinant IgG gene fragments from human lymphocytes, established a library, and selected one clone that was therapeutically effective at low doses using MPO-ANCA-related vasculitis model mice. We developed a novel recombinant antibody drug candidate, VasSF, and apolipoproteinA2 (APOA2) has been identified as one of VasSF's target molecules. Furthermore, we report that APOA2 was also found to be effective in Kawasaki disease model mice.
Journal
-
- ROKiVA Letter
-
ROKiVA Letter 4 (1), 4-8, 2024-04-01
Research Organization for Kidney and Vascular Ageing
- Tweet
Details 詳細情報について
-
- CRID
- 1390581489523005312
-
- ISSN
- 24367842
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
-
- Abstract License Flag
- Disallowed